Imunon (NASDAQ:IMNN – Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Imunon to announce earnings of ($0.61) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 11:00 AM ET.
Imunon (NASDAQ:IMNN – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.33. On average, analysts expect Imunon to post ($2.37) EPS for the current fiscal year and ($2.03) EPS for the next fiscal year.
Imunon Price Performance
Shares of NASDAQ IMNN opened at $0.91 on Thursday. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.82 and a quick ratio of 1.82. Imunon has a 1-year low of $0.81 and a 1-year high of $4.38. The stock’s 50-day moving average is $1.27 and its 200 day moving average is $2.20.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Imunon has a consensus rating of “Hold” and an average price target of $10.00.
Read Our Latest Analysis on IMNN
About Imunon
Imunon, Inc (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. The company uses proprietary nucleic acid delivery technologies to develop therapeutic candidates designed to stimulate the immune system or deliver genetic instructions directly to target cells.
Imunon’s lead program is GEN-1, an investigational interleukin-12 gene-mediated immunotherapy intended to treat ovarian cancer. The company has evaluated GEN-1 in combination with chemotherapy and other treatments in clinical studies.
Featured Stories
- Five stocks we like better than Imunon
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
